PRMT5 Inhibitor Compounds Selective Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective inhibitors for Protein Arginine Methyltransferase 5 (PRMT5), a key enzyme involved in various human diseases such as proliferative, metabolic, and blood disorders, which affects epigenetic regulation and gene expression.
Innovation Solution
Development of specific compounds, represented by Formula (I), that selectively inhibit PRMT5 activity, offering potential therapeutic benefits for PRMT5-mediated disorders by modulating its enzymatic function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PRMT5 inhibitors are developed to treat diseases, then therapeutic effectiveness is improved, but drug safety and toxicity concerns worsen
Solution Approach 1:
The patent modifies the chemical structure of PRMT5 inhibitors by changing parameters such as substituting aromatic rings with heteroaromatic rings, adjusting side chain lengths, and modifying functional groups. These parameter changes optimize the balance between binding affinity (therapeutic effectiveness) and off-target effects (toxicity), allowing selective inhibition of PRMT5 while minimizing harm to other biological systems.
2Reliability
If selective PRMT5 inhibition is achieved, then disease-specific treatment is improved, but off-target effects worsen
Solution Approach 1:
The patent introduces local quality modifications by adding specific functional groups or substituents at particular positions in the molecule that are critical for PRMT5 binding but not present in off-target proteins. This localized structural differentiation enables selective interaction with PRMT5's active site while avoiding binding to similar but non-target proteins, thereby reducing off-target effects.
3Ease of manufacture
If compound structure is simplified, then synthesis ease is improved, but binding affinity worsens
Solution Approach 1:
The patent divides the inhibitor molecule into distinct functional segments: a core scaffold providing structural stability, side chains responsible for binding affinity, and terminal groups affecting pharmacokinetics. This segmentation allows independent optimization of each component - simplifying the core for ease of synthesis while maintaining or enhancing side chain interactions with PRMT5 for binding affinity.
Data Source
AI summary
Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.